Pheochromocytoma
97
24
30
36
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
11 trials with published results (11%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.3%
9 terminated out of 97 trials
80.0%
-6.5% vs benchmark
8%
8 trials in Phase 3/4
31%
11 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (97)
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Diagnosis of Pheochromocytoma
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
DOTATOC PET/CT for Imaging NET Patients
Adrenal Tumors - Pathogenesis and Therapy
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Institutional Registry of Rare Diseases
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors